Article in Pulmonary circulation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
27 authors.
Lindsay M ForbesDivision of Pulmonary Sciences and Critical Care Medicine University of Colorado Aurora Colorado USA.ORCID 0000-0001-7367-0775
Natalie BauerDepartment of Pharmacology College of Medicine, University of South Alabama Mobile Alabama USA.
Aritra BhadraDepartment of Pharmacology College of Medicine, University of South Alabama Mobile Alabama USA.ORCID 0000-0002-6880-0894
Harm J BogaardDepartment of Pulmonary Medicine Amsterdam UMC Amsterdam Netherlands.
Gaurav ChoudharyDivision of Cardiology Warren Alpert Medical School of Brown University Providence Rhode Island USA.ORCID 0000-0001-9343-5481
Kara N GossDepartment of Medicine and Pediatrics University of Texas Southwestern Medical Center Dallas Texas USA.
Stefan GräfDivision of Computational Genomics and Genomic Medicine, Department of Medicine University of Cambridge, Victor Phillip Dahdaleh Heart & Lung Research Institute Cambridge UK.
Gustavo A HeresiDivision of Pulmonary Medicine Cleveland Clinic Cleveland Ohio USA.
Rachel K HopperDepartment of Pediatrics Stanford University School of Medicine Palo Alto California USA.ORCID 0000-0002-7483-2825
Arun JoseDivision of Pulmonary, Critical Care, and Sleep Medicine University of Cincinnati Cincinnati Ohio USA.
Yunhye KimDivision of Pulmonary Medicine Boston Children's Hospital Boston MA USA.
Timothy KloudaDivision of Pulmonary Medicine Boston Children's Hospital Boston MA USA.
Tim LahmDivision of Pulmonary Sciences and Critical Care Medicine University of Colorado Aurora Colorado USA.
Allan LawrieNational Heart and Lung Institute Imperial College London London UK.ORCID 0000-0003-4192-9505
Peter J LearyDepartments of Medicine and Epidemiology University of Washington Seattle Washington USA.ORCID 0000-0001-5716-248X
Jane A LeopoldDivision of Cardiovascular Medicine Brigham and Women's Hospital, Harvard Medical School Boston Massachusetts USA.
Suellen D OliveiraDepartment of Anesthesiology, Department of Physiology and Biophysics University of Illinois at Chicago Chicago Illinois USA.ORCID 0000-0002-7654-1909
Sasha Z PriscoDivision of Cardiovascular Lillehei Heart Institute, University of Minnesota Minneapolis Minnesota USA.ORCID 0000-0002-9059-0635
Ruslan RafikovDepartment of Medicine Indiana University Indianapolis Indiana USA.
Christopher J RhodesNational Heart and Lung Institute Imperial College London London UK.
Duncan J StewartOttawa Hospital Research Institute Faculty of Medicine University of Ottawa Ottawa Ontario Canada.
Rebecca R VanderpoolDivision of Cardiovascular Medicine The Ohio State University Columbus Ohio USA.ORCID 0000-0001-6038-0568
Ke YuanDivision of Pulmonary Medicine Boston Children's Hospital Boston MA USA.
Alexsandra ZimmerDepartment of Medicine Brown University Providence Rhode Island USA.
Anna R HemnesDivision of Allergy, Pulmonary and Critical Care Medicine Vanderbilt University Medical Center Nashville Tennessee USA.ORCID 0000-0002-2755-5845
Vinicio A de Jesus PerezDivision of Pulmonary and Critical Care Medicine Stanford University Medical Center Stanford California USA.
Martin R WilkinsNational Heart and Lung Institute Imperial College London London UK.
Funding
LCenter for Clinical and Translational Science and TrainingUL1TR001425 · NCATS · UNIVERSITY OF CINCINNATI · PI MEINZEN-DERR, JAREEN, STRAWN, JEFFREY ROBERT · 2015 to 2024
$37.5M
Colorado Clinical and Translational Sciences Institute (CCTSI)UM1TR004399 · NCATS · UNIVERSITY OF COLORADO DENVER · PI JANINE A HIGGINS, RONALD J. SOKOL · 2023 to 2026
$30.7M
The Wnt7a/ROR2 axis in the pathogenesis of pulmonary arterial hypertensionR01HL134776 · NHLBI · STANFORD UNIVERSITY · PI DE JESUS PEREZ, VINICIO A · 2017 to 2025
$5.0M
Endothelial-pericyte interactions in the pathogenesis of pulmonary arterial hypertensionR01HL139664 · NHLBI · STANFORD UNIVERSITY · PI DE JESUS PEREZ, VINICIO A · 2018 to 2025
$4.7M
Mechanisms of Right Ventricle Adaptation to Pulmonary HypertensionR01HL144727 · NHLBI · NATIONAL JEWISH HEALTH · PI Tim Lahm · 2019 to 2026
$4.7M
Anaplerotic reprogramming of endothelial cells in pulmonary hypertension.R01HL132918 · NHLBI · UNIVERSITY OF ARIZONA · PI RAFIKOV, RUSLAN · 2016 to 2025
$4.5M
Hemolysis and Free Heme Signaling in Pulmonary HypertensionR01HL151447 · NHLBI · UNIVERSITY OF ARIZONA · PI Ruslan Rafikov · 2020 to 2026
$4.3M
Intergrated Endothelial Phenotyping to Redefine Pulmonary HypertensionU01HL125215 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI LEOPOLD, JANE A, WAXMAN, AARON B · 2014 to 2018
$1.7M
The Role of the CES1 in the Pathogenesis of Pulmonary Arterial HypertensionR01HL172449 · NHLBI · STANFORD UNIVERSITY · PI VINICIO A DE JESUS PEREZ · 2024 to 2026
$1.6M
Biomarker Discovery in Portopulmonary HypertensionK23HL164971 · NHLBI · UNIVERSITY OF CINCINNATI · PI Arun Jose · 2023 to 2026
$822k
Generation of Endothelial Cell Memory in Inflammatory Vascular DiseaseK01HL159037 · NHLBI · UNIVERSITY OF ILLINOIS AT CHICAGO · PI DOS SANTOS OLIVEIRA, SUELLEN D'ARC · 2021 to 2025
$800k
Modulating the Microbiome to Enhance Right Ventricular Function in Pulmonary Arterial HypertensionK08HL168166 · NHLBI · UNIVERSITY OF MINNESOTA · PI Sasha Zheng Prisco · 2024 to 2026
Pulmonary vascular disease is not a single condition; rather it can accompany a variety of pathologies that impact the pulmonary vasculature. Applying precision medicine strategies to better phenotype, diagnose, monitor, and treat pulmonary vascular disease is increasingly possible with the growing accessibility of powerful clinical and research tools. Nevertheless, challenges exist in implementing these tools to optimal effect. The 2023 Grover Conference Series reviewed the research landscape to summarize the current state of the art and provide a better understanding of the application of precision medicine to managing pulmonary vascular disease. In particular, the following aspects were discussed: (1) Clinical phenotypes, (2) genetics, (3) epigenetics, (4) biomarker discovery, (5) application of precision biology to clinical trials, (6) the right ventricle (RV), and (7) integrating precision medicine to clinical care. The present review summarizes the content of these discussions and the prospects for the future.
Indexed as
biomarkerepigeneticsgenomics‐metabolomics‐proteomicspulmonary hypertensionright ventricle function and dysfunction
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.
Precision Medicine for Pulmonary Vascular Disease: The Future Is Now (2023 Grover Conference Series). · full record | Socratic